{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:38:46Z","timestamp":1792543126868,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12921-5","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:20:02Z","timestamp":1792495202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic potential of varenicline in neuropsychiatric disorders: insights into its molecular mechanisms"],"prefix":"10.1007","volume":"53","author":[{"given":"Abdolkarim","family":"Talebi Taheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rahmati-Dehkordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid Reza","family":"Tamtaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"16","key":"12921_CR1","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/cells12162051","volume":"12","author":"AS Vall\u00e9s","year":"2023","unstructured":"Vall\u00e9s AS, Barrantes FJ (2023) Nicotinic acetylcholine receptor dysfunction in addiction and in some neurodegenerative and neuropsychiatric diseases. Cells 12(16):2051","journal-title":"Cells"},{"issue":"4","key":"12921_CR2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/med.22108","volume":"45","author":"A Colleoni","year":"2025","unstructured":"Colleoni A et al (2025) Light-Activated Pharmacological Tools for Exploring the Cholinergic System. Med Res Rev 45(4):1251\u20131274","journal-title":"Med Res Rev"},{"key":"12921_CR3","unstructured":"Xu H et al (2025) Cholinergic system in patients with chronic kidney disease: cognitive and renal implications. Nephrol Dial Transplant"},{"key":"12921_CR4","doi-asserted-by":"crossref","unstructured":"Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors: from structure to brain function. Reviews of physiology, biochemistry and pharmacology, : pp. 1\u201346","DOI":"10.1007\/s10254-003-0005-1"},{"issue":"6","key":"12921_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pneurobio.2004.09.006","volume":"74","author":"C Gotti","year":"2004","unstructured":"Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74(6):363\u2013396","journal-title":"Prog Neurobiol"},{"key":"12921_CR6","doi-asserted-by":"publisher","first-page":"106764","DOI":"10.1016\/j.phrs.2023.106764","volume":"191","author":"AV Terry Jr","year":"2023","unstructured":"Terry AV Jr., Jones K, Bertrand D (2023) Nicotinic acetylcholine receptors in neurological and psychiatric diseases. Pharmacol Res 191:106764","journal-title":"Pharmacol Res"},{"key":"12921_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ejmech.2015.11.045","volume":"108","author":"C Matera","year":"2016","unstructured":"Matera C et al (2016) Modification of the anabaseine pyridine nucleus allows achieving binding and functional selectivity for the \u03b13\u03b24 nicotinic acetylcholine receptor subtype. Eur J Med Chem 108:392\u2013405","journal-title":"Eur J Med Chem"},{"issue":"12","key":"12921_CR8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1080\/10286020.2024.2371040","volume":"26","author":"Z Hui","year":"2024","unstructured":"Hui Z et al (2024) Mechanisms and therapeutic potential of chinonin in nervous system diseases. J Asian Nat Prod Res 26(12):1405\u20131420","journal-title":"J Asian Nat Prod Res"},{"issue":"1","key":"12921_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.31083\/j.fbl2701008","volume":"27","author":"Y Zhou","year":"2022","unstructured":"Zhou Y et al (2022) In vivo and in vitro neuroprotective effects of maca polysaccharide. Front Biosci (Landmark Ed) 27(1):8","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"5","key":"12921_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/1756285616651197","volume":"9","author":"A Bayas","year":"2016","unstructured":"Bayas A et al (2016) Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study-REGAIN. Ther Adv Neurol Disorder 9(5):378\u2013388","journal-title":"Ther Adv Neurol Disorder"},{"issue":"2","key":"12921_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11064-025-04338-6","volume":"50","author":"SZ Athari","year":"2025","unstructured":"Athari SZ et al (2025) Varenicline Attenuates Memory Impairment in Amyloid-Beta-Induced Rat Model of Alzheimer\u2019s Disease. Neurochem Res 50(2):86","journal-title":"Neurochem Res"},{"key":"12921_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.brainresbull.2022.01.010","volume":"181","author":"F Seyedaghamiri","year":"2022","unstructured":"Seyedaghamiri F et al (2022) Varenicline improves cognitive impairment in a mouse model of mPFC ischemia: The possible roles of inflammation, apoptosis, and synaptic factors. Brain Res Bull 181:36\u201345","journal-title":"Brain Res Bull"},{"issue":"6","key":"12921_CR13","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/brain\/awy099","volume":"141","author":"O Sabri","year":"2018","unstructured":"Sabri O et al (2018) Cognitive correlates of \u03b14\u03b22 nicotinic acetylcholine receptors in mild Alzheimer\u2019s dementia. Brain 141(6):1840\u20131854","journal-title":"Brain"},{"issue":"7704","key":"12921_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41586-018-0081-7","volume":"557","author":"RM Walsh Jr","year":"2018","unstructured":"Walsh RM Jr et al (2018) Structural principles of distinct assemblies of the human \u03b14\u03b22 nicotinic receptor. Nature 557(7704):261\u2013265","journal-title":"Nature"},{"issue":"45","key":"12921_CR15","doi-asserted-by":"publisher","first-page":"23452","DOI":"10.1074\/jbc.M116.749150","volume":"291","author":"A Jain","year":"2016","unstructured":"Jain A et al (2016) Unorthodox acetylcholine binding sites formed by \u03b15 and \u03b23 accessory subunits in \u03b14\u03b22* nicotinic acetylcholine receptors. J Biol Chem 291(45):23452\u201323463","journal-title":"J Biol Chem"},{"issue":"8","key":"12921_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/archpsyc.63.8.907","volume":"63","author":"AL Brody","year":"2006","unstructured":"Brody AL et al (2006) Cigarette smoking saturates brain \u03b14\u03b22 nicotinic acetylcholine receptors. Arch Gen Psychiatry 63(8):907\u2013914","journal-title":"Arch Gen Psychiatry"},{"issue":"30","key":"12921_CR17","doi-asserted-by":"publisher","first-page":"10891","DOI":"10.1523\/JNEUROSCI.0937-11.2011","volume":"31","author":"TM McGranahan","year":"2011","unstructured":"McGranahan TM et al (2011) \u03b14\u03b22 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief. J Neurosci 31(30):10891\u201310902","journal-title":"J Neurosci"},{"issue":"21","key":"12921_CR18","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1523\/JNEUROSCI.0364-17.2017","volume":"37","author":"Y Sun","year":"2017","unstructured":"Sun Y et al (2017) Nicotinic \u03b14\u03b22 cholinergic receptor influences on dorsolateral prefrontal cortical neuronal firing during a working memory task. J Neurosci 37(21):5366\u20135377","journal-title":"J Neurosci"},{"key":"12921_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00213-006-0416-1","volume":"188","author":"A Pocivavsek","year":"2006","unstructured":"Pocivavsek A, Icenogle L, Levin ED (2006) Ventral hippocampal \u03b17 and \u03b14\u03b22 nicotinic receptor blockade and clozapine effects on memory in female rats. Psychopharmacology 188:597\u2013604","journal-title":"Psychopharmacology"},{"issue":"4","key":"12921_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0306-4522(01)00538-3","volume":"109","author":"E Levin","year":"2002","unstructured":"Levin E et al (2002) Hippocampal \u03b17 and \u03b14\u03b22 nicotinic receptors and working memory. Neuroscience 109(4):757\u2013765","journal-title":"Neuroscience"},{"issue":"10","key":"12921_CR21","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1021\/jm050069n","volume":"48","author":"JW Coe","year":"2005","unstructured":"Coe JW et al (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48(10):3474\u20133477","journal-title":"J Med Chem"},{"issue":"5","key":"12921_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/ADM.0000000000001171","volume":"17","author":"X Shang","year":"2023","unstructured":"Shang X et al (2023) Effectiveness and safety of varenicline for smoking cessation: an overview and meta-analysis. J Addict Med 17(5):536\u2013543","journal-title":"J Addict Med"},{"key":"12921_CR23","doi-asserted-by":"crossref","unstructured":"Perez XA et al (2015) Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal, vol 3. Pharmacology Research & Perspectives, p e00105. 1","DOI":"10.1002\/prp2.105"},{"issue":"3","key":"12921_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/mol.106.025130","volume":"70","author":"KB Mihalak","year":"2006","unstructured":"Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70(3):801\u2013805","journal-title":"Mol Pharmacol"},{"issue":"1","key":"12921_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1124\/jpet.111.185306","volume":"339","author":"SC Lummis","year":"2011","unstructured":"Lummis SC et al (2011) Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther 339(1):125\u2013131","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"12921_CR26","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1007\/s12035-022-02797-4","volume":"59","author":"Q Wang","year":"2022","unstructured":"Wang Q et al (2022) Nicotine activating \u03b14\u03b22 nicotinic acetylcholine receptors to suppress neuroinflammation via JAK2-STAT3 signaling pathway in ischemic rats and inflammatory cells. Mol Neurobiol 59(5):3280\u20133293","journal-title":"Mol Neurobiol"},{"key":"12921_CR27","doi-asserted-by":"publisher","first-page":"108105","DOI":"10.1016\/j.cmpb.2024.108105","volume":"247","author":"Z Guo","year":"2024","unstructured":"Guo Z et al (2024) Investigating the interpretability of schizophrenia EEG mechanism through a 3DCNN-based hidden layer features aggregation framework. Comput Methods Programs Biomed 247:108105","journal-title":"Comput Methods Programs Biomed"},{"key":"12921_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neuropharm.2018.09.044","volume":"143","author":"C Huang","year":"2018","unstructured":"Huang C et al (2018) Varenicline reduces DNA damage, tau mislocalization and post surgical cognitive impairment in aged mice. Neuropharmacology 143:217\u2013227","journal-title":"Neuropharmacology"},{"key":"12921_CR29","doi-asserted-by":"publisher","first-page":"178813","DOI":"10.1016\/j.ejphar.2026.178813","volume":"1021","author":"H Zhang","year":"2026","unstructured":"Zhang H et al (2026) TAK-242 alleviates neuroinflammation and poststroke cognitive impairment by targeting the TLR4\/SYK\/NF-\u03baB pathway in a cerebral ischemia\/reperfusion rat model. Eur J Pharmacol 1021:178813","journal-title":"Eur J Pharmacol"},{"key":"12921_CR30","doi-asserted-by":"publisher","first-page":"1255560","DOI":"10.3389\/fphar.2023.1255560","volume":"14","author":"G Wang","year":"2023","unstructured":"Wang G et al (2023) Total saponins from Trillium tschonoskii Maxim promote neurological recovery in model rats with post-stroke cognitive impairment. Front Pharmacol 14:1255560","journal-title":"Front Pharmacol"},{"key":"12921_CR31","doi-asserted-by":"crossref","unstructured":"Jurcau A, Ardelean AI (2022) Oxidative Stress in Ischemia\/Reperfusion Injuries following Acute Ischemic Stroke. Biomedicines 10(3):574.","DOI":"10.3390\/biomedicines10030574"},{"issue":"6","key":"12921_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4103\/0253-7613.19072","volume":"37","author":"A Venkatesham","year":"2005","unstructured":"Venkatesham A et al (2005) Effect of reactive oxygen species on cholinergic receptor function. Indian J Pharmacol 37(6):366\u2013370","journal-title":"Indian J Pharmacol"},{"key":"12921_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.fct.2019.02.012","volume":"125","author":"P Moyano","year":"2019","unstructured":"Moyano P et al (2019) Manganese induced ROS and AChE variants alteration leads to SN56 basal forebrain cholinergic neuronal loss after acute and long-term treatment. Food Chem Toxicol 125:583\u2013594","journal-title":"Food Chem Toxicol"},{"key":"12921_CR34","doi-asserted-by":"crossref","unstructured":"Zhou J et al (2026) SIRT1: An Emerging Role in Regulated Cell Death in Ischemic Stroke. CNS Neurol Disord Drug Targets","DOI":"10.2174\/0118715273418707251202102848"},{"key":"12921_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neuropharm.2016.03.025","volume":"107","author":"C Lange-Asschenfeldt","year":"2016","unstructured":"Lange-Asschenfeldt C et al (2016) Effects of varenicline on alpha4-containing nicotinic acetylcholine receptor expression and cognitive performance in mice. Neuropharmacology 107:100\u2013110","journal-title":"Neuropharmacology"},{"issue":"10","key":"12921_CR36","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1093\/brain\/awt195","volume":"136","author":"H Okada","year":"2013","unstructured":"Okada H et al (2013) Alterations in \u03b14\u03b22 nicotinic receptors in cognitive decline in Alzheimer\u2019s aetiopathology. Brain 136(10):3004\u20133017","journal-title":"Brain"},{"issue":"36","key":"12921_CR37","doi-asserted-by":"publisher","first-page":"37842","DOI":"10.1074\/jbc.M400335200","volume":"279","author":"J Wu","year":"2004","unstructured":"Wu J et al (2004) \u03b2-Amyloid directly inhibits human \u03b14\u03b22-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem 279(36):37842\u201337851","journal-title":"J Biol Chem"},{"key":"12921_CR38","doi-asserted-by":"crossref","unstructured":"Roberts JP et al (2021) Selective coactivation of \u03b17-and \u03b14\u03b22-nicotinic acetylcholine receptors reverses beta-amyloid\u2013induced synaptic dysfunction. J Biol Chem 296:100402.","DOI":"10.1016\/j.jbc.2021.100402"},{"issue":"4","key":"12921_CR39","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/pr.110.003269","volume":"63","author":"M Quik","year":"2011","unstructured":"Quik M, Wonnacott S (2011) \u03b16\u03b22* and \u03b14\u03b22* nicotinic acetylcholine receptors as drug targets for Parkinson\u2019s disease. Pharmacol Rev 63(4):938\u2013966","journal-title":"Pharmacol Rev"},{"issue":"8","key":"12921_CR40","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/archgenpsychiatry.2009.106","volume":"66","author":"PM Meyer","year":"2009","unstructured":"Meyer PM et al (2009) Reduced \u03b14\u03b22*\u2013nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66(8):866\u2013877","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"12921_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/ane.12259","volume":"130","author":"R Lorenz","year":"2014","unstructured":"Lorenz R et al (2014) Nicotinic \u03b14\u03b22 acetylcholine receptors and cognitive function in Parkinson\u2019s disease. Acta Neurol Scand 130(3):164\u2013171","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"12921_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X (2025) Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell 16(2):83\u2013120","journal-title":"Protein Cell"},{"key":"12921_CR43","doi-asserted-by":"crossref","unstructured":"Better MA (2023) Alzheimer\u2019s disease facts and figures. Alzheimers Dement 19(4):1598\u20131695","DOI":"10.1002\/alz.13016"},{"key":"12921_CR44","doi-asserted-by":"publisher","first-page":"1263771","DOI":"10.3389\/fnins.2023.1263771","volume":"17","author":"A Pless","year":"2023","unstructured":"Pless A et al (2023) Understanding neuropsychiatric symptoms in Alzheimer\u2019s disease: challenges and advances in diagnosis and treatment. Front Neurosci 17:1263771","journal-title":"Front Neurosci"},{"issue":"5","key":"12921_CR45","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1734-1140(12)70904-0","volume":"64","author":"M Kruk-S\u0142omka","year":"2012","unstructured":"Kruk-S\u0142omka M, Budzy\u0144ska B, Bia\u0142a G (2012) Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice. Pharmacol Rep 64(5):1066\u20131080","journal-title":"Pharmacol Rep"},{"issue":"1","key":"12921_CR46","first-page":"48","volume":"3","author":"T Baluchnejadmojarad","year":"2011","unstructured":"Baluchnejadmojarad T et al (2011) Varenicline Ameliorates Learning and Memory Deficits in Amyloid \u03b2 (25\u201335) Rat Model of Alzheimer\u2019s Disease. Basic Clin Neurosci 3(1):48","journal-title":"Basic Clin Neurosci"},{"issue":"3\u20134","key":"12921_CR47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000355373","volume":"37","author":"SY Kim","year":"2014","unstructured":"Kim SY et al (2014) Phase II crossover trial of varenicline in mild-to-moderate Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 37(3\u20134):232\u2013245","journal-title":"Dement Geriatr Cogn Disord"},{"key":"12921_CR48","doi-asserted-by":"publisher","first-page":"117827","DOI":"10.1016\/j.biopha.2025.117827","volume":"183","author":"DC Joshi","year":"2025","unstructured":"Joshi DC et al (2025) The role of mitochondrial dysfunction in Huntington\u2019s disease: Implications for therapeutic targeting. Biomed Pharmacother 183:117827","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"12921_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00702-024-02744-8","volume":"131","author":"KA Jellinger","year":"2024","unstructured":"Jellinger KA (2024) Mild cognitive impairment in Huntington\u2019s disease: challenges and outlooks. J Neural Transm (Vienna) 131(4):289\u2013304","journal-title":"J Neural Transm (Vienna)"},{"issue":"8","key":"12921_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","volume":"24","author":"J Saade","year":"2024","unstructured":"Saade J, Mestre TA (2024) Huntington\u2019s Disease: Latest Frontiers in Therapeutics. Curr Neurol Neurosci Rep 24(8):255\u2013264","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"12921_CR51","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1080\/15548627.2020.1728096","volume":"17","author":"S Franco-Iborra","year":"2021","unstructured":"Franco-Iborra S et al (2021) Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease. Autophagy 17(3):672\u2013689","journal-title":"Autophagy"},{"issue":"3","key":"12921_CR52","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12640-017-9766-1","volume":"32","author":"M Jodeiri Farshbaf","year":"2017","unstructured":"Jodeiri Farshbaf M, Ghaedi K (2017) Huntington\u2019s disease and mitochondria. Neurotox Res 32(3):518\u2013529","journal-title":"Neurotox Res"},{"key":"12921_CR53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuropharm.2016.12.021","volume":"116","author":"AL McGregor","year":"2017","unstructured":"McGregor AL et al (2017) Varenicline improves motor and cognitive deficits and decreases depressive-like behaviour in late-stage YAC128 mice. Neuropharmacology 116:233\u2013246","journal-title":"Neuropharmacology"},{"key":"12921_CR54","doi-asserted-by":"crossref","unstructured":"McGregor AL et al (2016) Varenicline improves motor and cognitive symptoms in early Huntington\u2019s disease. Neuropsychiatr Dis Treat 12:2381\u20132386","DOI":"10.2147\/NDT.S111083"},{"issue":"10291","key":"12921_CR55","first-page":"2284","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease Lancet 397(10291):2284\u20132303","journal-title":"Parkinson\u2019s disease Lancet"},{"key":"12921_CR56","doi-asserted-by":"publisher","first-page":"1464706","DOI":"10.3389\/fnagi.2024.1464706","volume":"16","author":"R Sheta","year":"2024","unstructured":"Sheta R et al (2024) Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson\u2019s disease. Front Aging Neurosci 16:1464706","journal-title":"Front Aging Neurosci"},{"issue":"14supplement1","key":"12921_CR57","first-page":"S3","volume":"86","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Fahn S (2016) Levodopa therapy for Parkinson disease: a look backward and forward. Neurology 86(14supplement1):S3\u2013S12","journal-title":"Neurology"},{"issue":"4","key":"12921_CR58","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1515\/jbcpp-2017-0107","volume":"29","author":"AK Sharma","year":"2018","unstructured":"Sharma AK et al (2018) Haloperidol-induced parkinsonism is attenuated by varenicline in mice. J Basic Clin Physiol Pharmacol 29(4):395\u2013401","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"4","key":"12921_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/FBP.0000000000000355","volume":"29","author":"R Tan","year":"2018","unstructured":"Tan R et al (2018) Effect of varenicline on behavioral deficits in a rat model of Parkinson\u2019s disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra. Behav Pharmacol 29(4):327\u2013335","journal-title":"Behav Pharmacol"},{"issue":"1","key":"12921_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/apd.2022.111001","volume":"11","author":"ZM Altunay","year":"2022","unstructured":"Altunay ZM et al (2022) Effect of varenicline on detrusor overactivity in rat model of Parkinson\u2019s disease induced by intranigral 6-hydroxydopamine. Adv Parkinson\u2019s Disease 11(1):1\u201310","journal-title":"Adv Parkinson\u2019s Disease"},{"key":"12921_CR61","doi-asserted-by":"publisher","first-page":"e11679","DOI":"10.1590\/1414-431x2021e11679","volume":"54","author":"A Ribeiro-Carvalho","year":"2021","unstructured":"Ribeiro-Carvalho A et al (2021) Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson\u2019s disease. Braz J Med Biol Res 54:e11679","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"12921_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.26102","volume":"90","author":"RL Albin","year":"2021","unstructured":"Albin RL et al (2021) \u03b14\u03b22* nicotinic cholinergic receptor target engagement in Parkinson disease gait\u2013balance disorders. Ann Neurol 90(1):130\u2013142","journal-title":"Ann Neurol"},{"issue":"6","key":"12921_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/CPJ.0000000000000958","volume":"11","author":"S Kapur","year":"2021","unstructured":"Kapur S et al (2021) Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease. Neurol Clin Pract 11(6):457\u2013461","journal-title":"Neurol Clin Pract"},{"key":"12921_CR64","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jconrel.2024.03.050","volume":"369","author":"W Zhang","year":"2024","unstructured":"Zhang W et al (2024) Remodeling brain pathological microenvironment to lessen cerebral ischemia injury by multifunctional injectable hydrogels. J Control Release 369:591\u2013603","journal-title":"J Control Release"},{"issue":"1","key":"12921_CR65","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","volume":"5","author":"BC Campbell","year":"2019","unstructured":"Campbell BC et al (2019) Ischaemic stroke. Nat reviews Disease primers 5(1):70","journal-title":"Nat reviews Disease primers"},{"issue":"10328","key":"12921_CR66","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)02141-3","volume":"399","author":"H Herrman","year":"2022","unstructured":"Herrman H et al (2022) Time for united action on depression: a Lancet-World Psychiatric Association Commission. Lancet 399(10328):957\u20131022","journal-title":"Lancet"},{"issue":"2","key":"12921_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GMD Collaborators","year":"2022","unstructured":"Collaborators GMD (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9(2):137\u2013150","journal-title":"Lancet Psychiatry"},{"issue":"Pt B","key":"12921_CR68","doi-asserted-by":"publisher","first-page":"109436","DOI":"10.1016\/j.intimp.2022.109436","volume":"113","author":"L Wang","year":"2022","unstructured":"Wang L et al (2022) Pexidartinib (PLX3397) through restoring hippocampal synaptic plasticity ameliorates social isolation-induced mood disorders. Int Immunopharmacol 113(Pt B):109436","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"12921_CR69","doi-asserted-by":"publisher","first-page":"tfad126","DOI":"10.1093\/toxres\/tfad126","volume":"13","author":"A Mesripour","year":"2024","unstructured":"Mesripour A, Soltani L, Aliomrani M (2024) Bupropion and varenicline administration reversed depressive behavior induced by acetamiprid exposure in mice: the role of nAChRs in depression. Toxicol Res 13(1):tfad126","journal-title":"Toxicol Res"},{"issue":"2","key":"12921_CR70","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrn2774","volume":"11","author":"PJ Uhlhaas","year":"2010","unstructured":"Uhlhaas PJ, Singer W (2010) Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 11(2):100\u2013113","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"12921_CR71","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR et al (2014) Schizophrenia: overview and treatment options. Pharm Ther 39(9):638","journal-title":"Pharm Ther"},{"issue":"3","key":"12921_CR72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/138161210790170166","volume":"16","author":"RJ Radek","year":"2010","unstructured":"Radek RJ et al (2010) Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Design 16(3):309\u2013322","journal-title":"Curr Pharm Design"},{"issue":"3","key":"12921_CR73","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/npp.2011.238","volume":"37","author":"J-C Shim","year":"2012","unstructured":"Shim J-C et al (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37(3):660\u2013668","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"12921_CR74","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","volume":"110","author":"RC Smith","year":"2009","unstructured":"Smith RC et al (2009) Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 110(1\u20133):149\u2013155","journal-title":"Schizophr Res"},{"issue":"1","key":"12921_CR75","doi-asserted-by":"publisher","first-page":"e0143490","DOI":"10.1371\/journal.pone.0143490","volume":"11","author":"RC Smith","year":"2016","unstructured":"Smith RC et al (2016) Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial. PLoS ONE 11(1):e0143490","journal-title":"PLoS ONE"},{"issue":"12","key":"12921_CR76","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","volume":"68","author":"LE Hong","year":"2011","unstructured":"Hong LE et al (2011) Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 68(12):1195\u20131206","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"12921_CR77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.molbrainres.2004.01.003","volume":"123","author":"CM Martin-Ruiz","year":"2004","unstructured":"Martin-Ruiz CM et al (2004) Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res 123(1\u20132):81\u201390","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"12921_CR78","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/cap.2012.0025","volume":"23","author":"LE Arnold","year":"2013","unstructured":"Arnold LE, Anand R, Aman M (2013) Varenicline in autistic disorder: hypothesis and case report of single-patient crossover. J Child Adolesc Psychopharmacol 23(1):61\u201364","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"12921_CR79","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1089\/cap.2015.0230","volume":"26","author":"M Mostafavi","year":"2016","unstructured":"Mostafavi M, Hardy P, Arnold LE (2016) Varenicline in Autism: Theory and Case Report of Clinical and Biochemical Changes. J Child Adolesc Psychopharmacol 26(9):792\u2013797","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"12921_CR80","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1002\/npr2.70002","volume":"45","author":"Y Amano","year":"2025","unstructured":"Amano Y et al (2025) Effectiveness of Attentional Bias Modification Combined With Cognitive Behavioral Therapy in Reducing Relapse Risk and Cravings in Male Patients With Alcohol Use Disorder: A Quasi-Randomized Controlled Trial. Neuropsychopharmacol Rep 45(1):e70002","journal-title":"Neuropsychopharmacol Rep"},{"key":"12921_CR81","doi-asserted-by":"crossref","unstructured":"Yang W et al (2022) Alcohol Use Disorder: Neurobiology and Therapeutics. Biomedicines 10(5):1192.","DOI":"10.3390\/biomedicines10051192"},{"key":"12921_CR82","doi-asserted-by":"crossref","unstructured":"Essa H et al (2024) Impact of alcohol use disorder on cognition in correlation with aging: a community-based retrospective cohort study. Alcohol Alcohol 60(1):agae080","DOI":"10.1093\/alcalc\/agae080"},{"issue":"1","key":"12921_CR83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.nlm.2008.03.002","volume":"90","author":"D Gulick","year":"2008","unstructured":"Gulick D, Gould TJ (2008) Varenicline ameliorates ethanol-induced deficits in learning in C57BL\/6 mice. Neurobiol Learn Mem 90(1):230\u2013236","journal-title":"Neurobiol Learn Mem"},{"key":"12921_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.alcohol.2018.02.006","volume":"71","author":"KS Montgomery","year":"2018","unstructured":"Montgomery KS et al (2018) Effects of ethanol and varenicline on female Sprague-Dawley rats in a third trimester model of fetal alcohol syndrome. Alcohol 71:75\u201387","journal-title":"Alcohol"},{"issue":"1","key":"12921_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1037\/pha0000161","volume":"26","author":"W Roberts","year":"2018","unstructured":"Roberts W, McKee SA (2018) Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes. Exp Clin Psychopharmacol 26(1):49","journal-title":"Exp Clin Psychopharmacol"},{"issue":"7","key":"12921_CR86","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/acer.13110","volume":"40","author":"TL Verplaetse","year":"2016","unstructured":"Verplaetse TL et al (2016) Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings. Alcohol Clin Exp Res 40(7):1567\u20131576","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"12921_CR87","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1570159X15666171103152136","volume":"16","author":"G Valentine","year":"2018","unstructured":"Valentine G, Sofuoglu M (2018) Cognitive Effects of Nicotine: Recent Progress. Curr Neuropharmacol 16(4):403\u2013414","journal-title":"Curr Neuropharmacol"},{"key":"12921_CR88","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.brainres.2018.12.002","volume":"1710","author":"MR Zarrindast","year":"2019","unstructured":"Zarrindast MR, Khakpai F (2019) The modulatory role of nicotine on cognitive and non-cognitive functions. Brain Res 1710:92\u2013101","journal-title":"Brain Res"},{"issue":"1","key":"12921_CR89","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-publhealth-031816-044618","volume":"38","author":"JJ Prochaska","year":"2017","unstructured":"Prochaska JJ, Das S, Young-Wolff KC (2017) Smoking, mental illness, and public health. Annu Rev Public Health 38(1):165\u2013185","journal-title":"Annu Rev Public Health"},{"key":"12921_CR90","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neubiorev.2015.06.004","volume":"58","author":"FS Hall","year":"2015","unstructured":"Hall FS et al (2015) Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehavioral Reviews 58:168\u2013185","journal-title":"Neurosci Biobehavioral Reviews"},{"issue":"5","key":"12921_CR91","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1037\/a0012601","volume":"122","author":"JD Raybuck","year":"2008","unstructured":"Raybuck JD et al (2008) Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL\/6 mice. Behav Neurosci 122(5):1166","journal-title":"Behav Neurosci"},{"issue":"1","key":"12921_CR92","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1037\/a0025594","volume":"20","author":"RL Ashare","year":"2012","unstructured":"Ashare RL, McKee SA (2012) Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. Exp Clin Psychopharmacol 20(1):63","journal-title":"Exp Clin Psychopharmacol"},{"key":"12921_CR93","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00213-020-05451-w","volume":"237","author":"M Thompson","year":"2020","unstructured":"Thompson M et al (2020) The effect of varenicline on mood and cognition in smokers with HIV. Psychopharmacology 237:1223\u20131231","journal-title":"Psychopharmacology"},{"issue":"10","key":"12921_CR94","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/pon.4166","volume":"26","author":"S Price","year":"2017","unstructured":"Price S et al (2017) The use of varenicline to treat nicotine dependence among patients with cancer. Psycho-oncology 26(10):1526\u20131534","journal-title":"Psycho-oncology"},{"issue":"2","key":"12921_CR95","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/00952990.2012.750665","volume":"39","author":"KJ Hartwell","year":"2013","unstructured":"Hartwell KJ et al (2013) Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study. Am J Drug Alcohol Abuse 39(2):92\u201398","journal-title":"Am J Drug Alcohol Abuse"},{"key":"12921_CR96","doi-asserted-by":"publisher","first-page":"174524","DOI":"10.1016\/j.ejphar.2021.174524","volume":"916","author":"J Wang","year":"2022","unstructured":"Wang J et al (2022) Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice. Eur J Pharmacol 916:174524","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"12921_CR97","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bbr.2011.04.012","volume":"223","author":"J King","year":"2011","unstructured":"King J et al (2011) A comparison of brain and behavioral effects of varenicline and nicotine in rats. Behav Brain Res 223(1):42\u201347","journal-title":"Behav Brain Res"},{"key":"12921_CR98","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00213-015-4154-0","volume":"233","author":"AV Terry","year":"2016","unstructured":"Terry AV, Plagenhoef M, Callahan PM (2016) Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys. Psychopharmacology 233:761\u2013771","journal-title":"Psychopharmacology"},{"issue":"2","key":"12921_CR99","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.biopsych.2008.08.028","volume":"65","author":"F Patterson","year":"2009","unstructured":"Patterson F et al (2009) Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 65(2):144\u2013149","journal-title":"Biol Psychiatry"},{"issue":"11","key":"12921_CR100","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.biopsych.2010.12.005","volume":"69","author":"D Garza","year":"2011","unstructured":"Garza D et al (2011) A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 69(11):1075\u20131082","journal-title":"Biol Psychiatry"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12921-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:03:57Z","timestamp":1792541037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12921"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12921-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"15 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a review study. The TUMS Research Ethics Committee has confirmed that no ethical approval is required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1762"}}